IMMU-18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN GLIOMAS

Innate-based immunotherapies are becoming increasingly important for treating brain tumor patients. About 50% of WHO grade II and III gliomas carry mutations in IDH1 and ATRX genes. Mutant IDH1 results in the production of 2-hydroxyglutarate, an oncometabolite that promotes global metabolic and epig...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Hariharan, Seethalakshmi, Bowie, Michelle, Hostettler, Janell, Roso, Kristen, He, Yiping, Roskoski, Martin A, Charbonneau, Casey, Keir, Stephen, Brown, Michael, Irvin, David, Zhang, Gao, Gromeier, Matthias, Huse, Jason, Ashley, David
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2020
Sujets:
Immunology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651589/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.448
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires